Novel biologic agents blocking the production or action of such cytokines, including, for instance, IL-5, IL-5Rα, IL-33 and immunoglobulin (Ig)E, have been developed and examined for treatment of chronic rhinosinusitis-related nasal polyps [76]. The gene discussed is IL33; the disease is nasal cavity polyp.